Tubulis will receive $22.75M up front, ~$1B in development, regulatory & commercial milestones along with royalty on net product sales
BMS will obtain an exclusive right to access Tubulis’ Tubutecan payloads in combination with the P5 conjugation platform to develop selected no. of highly differentiated ADCs for solid tumors & will lead the development, manufacturing & commercialization of the resulting ADC candidates. Once BMS selects Ab targets, Tubulis will provide its linker payload to generate a uniquely matched ADC for each Ab
The collaboration combines BMS’ deep oncology & clinical development expertise & Tubulis’ differentiated and unique approach to ADC design to delivers ADC therapies
Ref: Businesswire | Image: Tubulis
Related News:- BMS Receives EMA’s CHMP Positive Opinion of Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma
